Sutro Biopharma STRO Institutional Ownership

Updated Oct 11, 2026

Sutro Biopharma, Inc. (NASDAQ:STRO) counted 100 institutional investors among its 13F-reported shareholders for the quarter ended June 30, 2026.

• Together they owned 99.42% of the outstanding stock in Q2 2026, up from 86.83% a quarter earlier.
• Total shares held in STRO rose 14.56% from Q1 2026; the number of holders rose 2.04% from Q2 2025.
• Of the 100 holders of STRO in Q2 2026, 67 added to their positions, 17 reduced their stakes and 16 left their positions unchanged.
• Institutional investors held 16.48Mn shares of Sutro Biopharma in total at the end of Q2 2026, up 2.09Mn from the prior quarter and up 10.95Mn from a year earlier.
• Perceptive Advisors LLC led 13F holders of STRO with 1.3Mn shares as of June 30, 2026, or 7.87% of shares outstanding.
• The biggest increases in STRO positions during Q2 2026 came from BlackRock, Inc. (+889.97K shares), Perceptive Advisors LLC (+589.54K shares), State Street Corp (+253.86K shares), Balyasny Asset Management L.P. (+245.37K shares) and Geode Capital Management, LLC (+218.31K shares).
• Holders that trimmed the most shares of Sutro Biopharma in Q2 2026 while keeping a position were Point72 Asset Management, L.P. (-454.28K shares), UBS Group AG (-184.36K shares), Eventide Asset Management, LLC (-130.04K shares), ADAR1 Capital Management, LLC (-120.43K shares) and Susquehanna International Group, LLP (-76.48K shares).
• Sutro Biopharma's 10 largest institutional shareholders as of Q2 2026 were Perceptive Advisors LLC (1.3Mn shares), BVF Inc (1.25Mn shares), Affinity Asset Advisors, LLC (1.17Mn shares), BlackRock, Inc. (1.12Mn shares), Samsara BioCapital, LLC (1.06Mn shares), Kynam Capital Management, LP (872.56K shares), OrbiMed Advisors LLC (743.94K shares), Balyasny Asset Management L.P. (711.16K shares), Vanguard Capital Management LLC (694.22K shares) and Eventide Asset Management, LLC (585.26K shares), per Business Quant data.